New research has identified three distinct clinical clusters of systemic lupus erythematosus (SLE) patients with different disease trajectories and outcomes. The study provides insights into disease progression, stable phenotypic clusters associated with specific autoantibody profiles and prognoses and helps explain the heterogeneity of treatment responses among patients, potentially optimizing therapeutic decisions for personalized medicine in SLE.

Source: RMD Open